Successful Management of Bleeding after Dental Procedures with Application of Blood Stopper: A Single Center Prospective Trial

Abstract

Aim Ankaferd Blood Stopper (ABS), as an herbal complementary medicine, has been approved for the management of clinical hemorrhages in Turkey, including dental interventions. Basic, preclinical and clinical studies disclosed the settings of the topical hemostatic use of ABS. The aim of this study is therefore to assess the efficacy and safety of ABS as an antihemorrhagic agent in the bleedings associated with dental procedures in patients with normal and impaired hemostasis. Materials and methods ABS has been topically applied by homogeneously spraying to the 113 patients during dental interventions within its on-label indications. A median of 0.5 ml (IQR:0.5-1 ml) ABS was administered after tooth extraction with prolonged hemorrhages. Results After the administration, bleeding stopped in less than 10 seconds in 59 (52.2%) patients, and below 22.5 seconds (IQR: 18, 8-30) in 54 patients (47.8%). A total of 141 procedures were performed in these 113 patients, and nearly 72.5 ml ABS was used with a total cost of 98 €. Conclusion ABS as a new herbal medicine was found to be an effective method for controlling bleeding related to dental procedures. No patient had wound infection and the healing process appeared to be normal. Topical ABS could be useful for the local hemostasis and wound healing in periodontal surgeries. Clinical significance In this prospective study ABS, for the first time, has demonstrated its potential for being an effective hemostatic agent for the management of bleedings due to dental procedures. How to cite this article Beyazit Y, Kart T, Kuscu A, Arslan A, Kurt M, Aktas B, Kekilli M, Haznedaroglu I. Successful Management of Bleeding after Dental Procedures with Application of Blood Stopper: A Single Center Prospective Trial. J Contemp Dent Pract 2011;12(5):379-384.

Successful Treatment of Refractory Gastrointestinal Bleeding by Systemic (Oral) Ankaferd Blood Stopper in a Patient with Glanzmann Thrombasthenia

“…The success of ABS in patients with a normal hemostatic system was mostly shown for gastrointestinal bleeds (3) and dental applications (4). All of these applications were local administrations, with a median ABS amount of between 1 mL and 20-30 mL.…”

Non-Surgical Periodontal Therapy With Ankaferd Blood Stopper In Patients With Bleeding Disorder: A Case Series

“…15 Son zamanlarda birçok olgu raporunda da belirtildiği gibi, tıpta ve diş hekimliğinde AKD'nin kanama kontrolündeki başarısı dikkate değer bulunmuştur. 4,12,15,16 Çalışmalar AKD'nin kanama bozukluğu olan hastalarda ilave ilaç ihtiyacını ve tedavi maliyetini azalttığını belirtmektedir. 12 Bu olgu serisinde de, cerrahi olmayan periodontal tedavi ne koagülasyon ilaçları ne de postoperatif koagülasyon faktörü yüklemesi yapılmadan gerçekleştirildi.…”

“…4,12,15,16 Çalışmalar AKD'nin kanama bozukluğu olan hastalarda ilave ilaç ihtiyacını ve tedavi maliyetini azalttığını belirtmektedir. 12 Bu olgu serisinde de, cerrahi olmayan periodontal tedavi ne koagülasyon ilaçları ne de postoperatif koagülasyon faktörü yüklemesi yapılmadan gerçekleştirildi. Cerrahi olmayan periodontal tedaviyi takiben oluşan kanama lokal AKD uygulaması ile kontrol altına alındı.…”

“…Yapılan çalışmalarda, AKD'nin deneysel ve topikal uygulamasında herhangi bir lokal ve sistemik yan etki ve/veya toksisite bildirilmemiştir. 12 Bu olgu serisi çalışmasının amacı, kanama bozukluğu olan hastalarda cerrahi olmayan periodontal tedaviyi takiben oluşan kanamayı kontrol altına almak için lokal AKD uygulamasının etkilerini değerlendirmektir. …”

“…12,17 Plazma kaynaklı pıhtılaşma faktörleri ve fibrinojen, viral infeksiyon geçiş riski ve pıhtılaşma faktör inhibitörlerinin oluşum riskini taşıyabilir.…”